Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial to Evaluate Safety and Effect of Personalized Neoantigen Vaccine for Pancreatic Tumor Following Surgical Resection and Adjuvant Chemotherapy

NCT03558945 is registered in ClinicalTrials.gov with Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. as lead sponsor.

NCT NCT03558945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03558945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial to Evaluate Safety and Effect of Personalized Neoantigen Vaccine for Pancreatic Tumor Following Surgical Resection and Adjuvant Chemotherapy
Lead sponsor
Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 12, 2018
Completion date
December 30, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic tumor